drugset / Trial / NCT05020652
A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Q05105 tablet is a Janus kinase 2 (JAK2) inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis
Timeline
- Start
- 2021-11-11
- Primary completion
- 2023-10-15
- Completion
- 2023-12-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Hydroxyurea | Other / unclassified | — | Oral |
| Subject | TQ05105 | Small molecule | — | Oral |